Literature DB >> 17382388

Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.

M Breccia, M Muscaritoli, F Gentilini, R Latagliata, I Carmosino, F Rossi Fanelli, G Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17382388     DOI： 10.1016/j.leukres.2007.01.024

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  16 in total

1.  Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.

Authors:  Peter Valent
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

Review 2.  Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Authors:  Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub
Journal:  Circulation       Date:  2019-03-26       Impact factor: 29.690

Review 3.  From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Authors:  Carlo Gabriele Tocchetti; Christian Cadeddu; Daniela Di Lisi; Saveria Femminò; Rosalinda Madonna; Donato Mele; Ines Monte; Giuseppina Novo; Claudia Penna; Alessia Pepe; Paolo Spallarossa; Gilda Varricchi; Concetta Zito; Pasquale Pagliaro; Giuseppe Mercuro
Journal:  Antioxid Redox Signal       Date:  2017-05-15       Impact factor: 8.401

Review 4.  Lifelong TKI therapy: how to manage cardiovascular and other risks.

Authors:  Michael J Mauro
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

5.  Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study.

Authors:  Mei-Tsen Chen; Shih-Tsung Huang; Chih-Wan Lin; Bor-Sheng Ko; Wen-Jone Chen; Huai-Hsuan Huang; Fei-Yuan Hsiao
Journal:  Oncologist       Date:  2021-09-12

Review 6.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

7.  Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib.

Authors:  Tilde Kristensen; Else Randers; Jesper Stentoft
Journal:  Leuk Res Rep       Date:  2012-11-10

8.  Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database.

Authors:  Naoto Okada; Takahiro Niimura; Yoshito Zamami; Hirofumi Hamano; Shunsuke Ishida; Mitsuhiro Goda; Kenshi Takechi; Masayuki Chuma; Masaki Imanishi; Keisuke Ishizawa
Journal:  Cancer Med       Date:  2018-12-18       Impact factor: 4.452

9.  Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.

Authors:  Tomohiko Ozaki; Hajime Nakamura; Nobuyuki Izutsu; Hiroaki Masaie; Jun Ishikawa; Manabu Kinoshita
Journal:  Interv Neuroradiol       Date:  2017-06-05       Impact factor: 1.610

10.  Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin.

Authors:  Yoshikiyo Ito; Toshihiro Miyamoto; Yong Chong; Toshinobu Maki; Koichi Akashi; Tomohiko Kamimura
Journal:  Int J Hematol       Date:  2012-11-23       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.